One Technology Place
202 articles with EMD Serono
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, is pleased to announce the appointment of Manuel Zafra as the new Managing Director for Canada.
Embracing Carers™, a global initiative led by EMD Serono, raises awareness about the often-overlooked needs of unpaid caregivers and develops solutions collaboratively with global caregiving organizations.
Merck KGaA, Darmstadt, Germany, Recognized for Collaborative Cancer Research by CEO Roundtable on Cancer
The CEO Roundtable on Cancer has recognized the healthcare business of Merck KGaA, Darmstadt, Germany, operating as EMD Serono in the US and Canada, with the 2020 Dr. Charles A. Sanders Award for collaborative scientific research in cancer.
BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print in The New England Journal of Medicine.
EMD Serono to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis
- Company to present 54 abstracts across its MS portfolio - MAVENCLAD® (cladribine) tablets, Rebif® (interferon beta-1a) and investigational evobrutinib - New data and real-world evidence further characterize the efficacy and safety profiles of MAVENCLAD® - New MAVENCLAD® and Rebif® safety data to be shared regarding risk of respiratory viral infections
FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO®
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.
EMD Serono Initiates First Clinical Trial of TLR7 and 8 Inhibitor as a Potential Treatment for Severe Symptoms of Covid-19 Infection
- Novel mechanism will be studied for the first time to potentially show a reduction in the inflammatory response that can lead to 'cytokine storm' in patients with Covid-19 pneumonia - TLR7 and TLR8 are innate immune sensors that detect single-stranded (ss) RNA from viruses such as SARS-CoV-2 - Results from the Phase II study expected by the end of 2020 [25-June-2020]
New England Journal of Medicine Publishes Primary Analysis of VISION Data for Tepotinib in Advanced NSCLC with METex14 Skipping Alterations
First publication of primary analysis shows robust and durable clinical response in patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations; data also presented during ASCO 2020
New Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor to Report Efficacy and Safety in MS Over 108 Weeks
Investigational evobrutinib is the first and only Bruton's Tyrosine Kinase inhibitor to demonstrate high and sustained efficacy through 108 weeks in clinical studies
Two-year follow-up for first-in-class bifunctional immunotherapy bintrafusp alfa‡ targeting TGF-β/PD-L1, in second-line NSCLC
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced data for its innovative investigational agents and investigational uses of marketed medicines to be presented at the American Society of Clinical Oncology (ASCO) ASCO20 Virtual Scientific Program, to be held virtually from May 29-31.
Late-breaking presentation of Phase III JAVELIN Bladder 100 data for BAVENCIO® showing overall survival benefit in first-line maintenance treatment of advanced urothelial carcinoma
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Breakthrough Therapy Designation and Submission based on positive Phase III JAVELIN Bladder 100 study results
EMD Serono announced that the Japanese Ministry of Health, Labour and Welfare has approved TEPMETKO®* for the treatment of patients with unresectable, advanced or recurrent non-small cell lung cancer with MET exon 14 skipping alterations.
3/16/2020Although news of the COVID-19 pandemic has tended to dominate the news cycle, including for the biopharma industry, there were a number of clinical trial announcements last week. Here’s a look.
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced an update from the Phase III JAVELIN Head and Neck 100 study evaluating avelumab in addition to chemoradiotherapy (CRT) versus standard-of-care CRT in patients with untreated locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)
The companies jointly announced that their Phase III JAVELIN Head and Neck 100 trial of Bavencio (avelumab) with chemoradiotherapy for untreated locally advanced squamous cell carcinoma of the head and neck was unlikely to hit the primary endpoint.
These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.
EMD Serono Receives Positive Recommendation for MAVENCLAD® (cladribine tablets) for the treatment of Relapsing-Remitting Multiple Sclerosis from the Institut national d'excellence en santé et en services sociaux (INESSS)
This decision brings PrMAVENCLAD® (cladribine tablets) closer to broader access for eligible patients living with Relapsing-Remitting Multiple Sclerosis in the province of Quebec